Literatur
- 1
Andre T, Colin P, Louvet C. et al .
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered
for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results
of a randomized trial.
J Clin Oncol.
2003;
21
2896-2903
- 2
Benson A B, Schrag D, Somerfield M R. et al .
American Society of Clinical Oncology recommendations on afdjuvant chemotherapy
for stage II colon cancer.
J Clin Oncol.
2004;
22
3408-3419
- 3
Cassidy J, Scheithauer W, McKendrick J. et al .
Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon
cancer: positive efficacy results of a phase III trial (abstr).
Proc ASCO.
2004;
23
247s
- 4
Cunningham D, Humblet Y, Siena D. et al .
Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients
with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory
metastatic colorectal cancer (MCRC) (abstr).
Proc ASCO.
2003;
22
256
- 5
DeGramont A, Figer A, Seymor M. et al .
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment
in advanced colorectal cancer.
J Clin Oncol.
2000;
18
2938-2947
- 6
DeGramont A, Banzi M, Navarro M, Tabernero J. et al .
Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized
mosaic trial (abstr).
Proc ASCO.
2003;
22
253
- 7
Douillard J Y, Hoff P M, Skillings J R. et al .
Multicenter phase III study of uracil/tegafur and oral leucovorin in patients
with previously untreated metastatic colorectal cancer.
J Clin Oncol.
2002;
20
3605-3616
- 8
Douillard J Y, Sobrero A, Carnaghi C. et al .
Metastatic colorectal cancer: integrating irinotecan into combination and sequential
chemotherapy.
Ann Oncol.
2003;
14
7-12
(Suppl 2)
- 9
Flieger D, Keller R, Fischbach W.
Aktuelle Therapiestrategien beim kolorektalen Karzinom.
Dtsch med Wochenschr.
2003;
128
1902-1907
- 10
Hejna M, Kornek G V, Raderer M. et al .
Reinduction therapy with the same cytostatic regimen in patients with advanced
colorectal cancer.
Br J Cancer.
1998;
78
760-764
- 11
Hoff P M.
Practical consdiderations in the use of oral fluoropyrimidines.
Semin Oncol.
2003;
30
88-92
(Suppl 6)
- 12
Hurwitz H, Fehrenbacher L, Cartwright T. et al .
Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs
survival in first-line colorectal cancer (CRC): results of a phase III trial
bevacizumab in combination with IFL (irinotecan, 5-fluorouracil, leucovorin)
as first-line therapy in subjects with metastatic CRC (abstr).
Proc ASCO.
2003;
22
254
- 13
Maughan T S, James R D, Kerr D J. et al .
Comparison of intermittent and continuous palliative chemotherapy for advanced
colorectal cancer: a multicentre randomised trial.
Lancet.
2003;
361
457-464
- 14
QUASAR.
A randomized study of adjuvant chemotherapy (CT) vs observation including 3238
colorectal cancer patients (abstr).
Proc ASCO.
2004;
23
245s
- 15
Rao S, Cunningham D.
Adjuvant therapy for colon cancer in the new millenium.
Scand J Surg.
2003;
92
57-64
- 16
Saini A, Normann A R, Cunninham D. et al .
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective
as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal
cancer.
Br J Cancer.
2003;
88
1859-1865
- 17
Scheithauer W, McKendrick J, Begbie S. et al .
Oral capecitabine as an alternative to i. v. 5-fluorouracil-based adjuvant therapy
for colon cancer: safety results of a randomized phase III trial.
Ann Oncol.
2003;
14
1735-1743
- 18
Simpson D, Dunn C, Curran M, Goa K L.
Oxaliplatin: a review of its use in combination chemotherapy for advanced colorectal
cancer.
Drugs.
2003;
63
2127-2156
- 19
Tournigand C, Andre T, Achille E. et al .
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:
a randomized GERCOR study.
J Clin Oncol.
2004;
22
229-237
Univ. Prof. Dr. Werner Scheithauer
Abteilung für Klinische Onkologie, Universitätsklinik für Innere Medizin I, Allgemeines
Krankenhaus
Währinger Gürtel 18-20
A-1090 Wien
Phone: 0043-1-40400-5462
Email: werner.scheithauer@meduniwien.ac.at
